Equities Analysts Offer Predictions for RCKT FY2025 Earnings

Key Points

• Chardan Capital has revised its FY2025 earnings forecast for Rocket Pharmaceuticals to ($2.01) per share, up from a previous estimate of ($2.04), and maintains a "Buy" rating with a price target of $11.00.
• Recent earnings showed Rocket Pharmaceuticals missed analyst expectations for the quarter, reporting ($0.59) EPS compared to a consensus of ($0.57).
• Institutional investors own 98.39% of Rocket Pharmaceuticals' stock, with several recently increasing their stakes significantly.

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) - Equities researchers at Chardan Capital raised their FY2025 EPS estimates for shares of Rocket Pharmaceuticals in a research note issued to investors on Monday, August 11th. Chardan Capital analyst Y. Livshits now forecasts that the biotechnology company will earn ($2.01) per share for the year, up from their previous forecast of ($2.04). Chardan Capital currently has a "Buy" rating and a $11.00 target price on the stock. The consensus estimate for Rocket Pharmaceuticals' current full-year earnings is ($2.83) per share. Chardan Capital also issued estimates for Rocket Pharmaceuticals' FY2026 earnings at ($1.19) EPS.

Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.02). During the same period in the previous year, the company posted ($0.74) EPS.

Several other analysts also recently weighed in on the company. Leerink Partnrs downgraded Rocket Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 27th. Cantor Fitzgerald dropped their target price on Rocket Pharmaceuticals from $10.00 to $8.00 and set an "overweight" rating for the company in a report on Friday, August 8th. JPMorgan Chase & Co. reissued a "neutral" rating on shares of Rocket Pharmaceuticals in a research note on Wednesday, May 28th. TD Cowen restated a "hold" rating on shares of Rocket Pharmaceuticals in a research note on Tuesday, May 27th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Rocket Pharmaceuticals in a report on Thursday, July 24th. Seven equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $16.33.

Rocket Pharmaceuticals Price Performance

RCKT traded down $0.1150 during trading on Thursday, reaching $2.9150. 1,102,098 shares of the company traded hands, compared to its average volume of 3,308,738. The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.39 and a current ratio of 6.39. Rocket Pharmaceuticals has a 12-month low of $2.19 and a 12-month high of $22.01. The firm has a fifty day simple moving average of $2.96 and a 200 day simple moving average of $5.79. The company has a market cap of $314.54 million, a P/E ratio of -1.17 and a beta of 0.65.

Insider Buying and Selling

In other Rocket Pharmaceuticals news, insider Jonathan David Schwartz sold 11,161 shares of the stock in a transaction that occurred on Thursday, August 14th. The stock was sold at an average price of $3.02, for a total transaction of $33,706.22. Following the transaction, the insider owned 224,094 shares of the company's stock, valued at $676,763.88. This trade represents a 4.74% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, General Counsel Martin Wilson sold 12,109 shares of the firm's stock in a transaction that occurred on Thursday, August 14th. The stock was sold at an average price of $3.02, for a total value of $36,569.18. Following the completion of the sale, the general counsel directly owned 137,054 shares in the company, valued at approximately $413,903.08. This trade represents a 8.12% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 31,790 shares of company stock worth $95,799. 24.76% of the stock is currently owned by company insiders.

Institutional Trading of Rocket Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Maverick Capital Ltd. grew its holdings in shares of Rocket Pharmaceuticals by 60.9% in the 2nd quarter. Maverick Capital Ltd. now owns 8,363,813 shares of the biotechnology company's stock worth $20,491,000 after acquiring an additional 3,164,595 shares during the last quarter. Suvretta Capital Management LLC acquired a new position in shares of Rocket Pharmaceuticals in the 4th quarter worth $32,267,000. MPM Bioimpact LLC grew its holdings in shares of Rocket Pharmaceuticals by 141.2% in the 2nd quarter. MPM Bioimpact LLC now owns 3,903,081 shares of the biotechnology company's stock worth $9,563,000 after acquiring an additional 2,284,816 shares during the last quarter. Janus Henderson Group PLC grew its holdings in shares of Rocket Pharmaceuticals by 111.0% in the 4th quarter. Janus Henderson Group PLC now owns 4,004,039 shares of the biotechnology company's stock worth $50,343,000 after acquiring an additional 2,106,699 shares during the last quarter. Finally, Point72 Asset Management L.P. grew its holdings in shares of Rocket Pharmaceuticals by 3,163.9% in the 4th quarter. Point72 Asset Management L.P. now owns 1,569,823 shares of the biotechnology company's stock worth $19,733,000 after acquiring an additional 1,521,727 shares during the last quarter. Institutional investors own 98.39% of the company's stock.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.